Navigation Links
Stem Cells Might Beat Drugs in Delivering Relief Faster, More Effectively to Rheumatoid Arthritis Sufferers
Date:4/16/2013

Durham, NC (PRWEB) April 16, 2013

Can stem cell therapy outperform a drug commonly considered the gold standard for treating rheumatoid arthritis? A new study in rodents published in the current issue of STEM CELLS Translational Medicine indicates perhaps so.

The findings could lead to a faster, safer, more effective way to bring relief to the up to 70 million people estimated to suffer from this disease worldwide.

Rheumatoid arthritis (RA) is a chronic condition that causes pain, stiffness, swelling and limited motion and function of many joints. While it can affect any joint, RA tends to settle mainly in a patient’s hands and feet. The results can be debilitating.

People who have RA overproduce a protein called tumor necrosis factor (TNF), which causes the inflammation and damage to the bones, cartilage and tissue. Anti-TNF drugs can block the action of the protein and reduce inflammation. Etanercept® (marketed under the trade name Enbrel) is a type of anti-TNF drug called a biologic that for years has been prescribed to treat RA. However, it can’t be targeted specifically to the site of the arthritis and, thus, requires higher doses that can cause serious side effects including fatal infections, multiple sclerosis, seizures, heart failure, cancer and more.

“Moreover, biologics in general require intense development and manufacturing processes that are challenging for reproducibility, even within the same company. So we wanted to see how delivering treatment through a very targeted system such as that which can be done using stem cells compared to a biologic drug such as Etanercept®,” said Joseph Mosca, Ph.D. He led the team of researchers from Osiris Therapeutics, Inc. Baltimore, Md., and the Novartis Research, Basel, Switzerland, in conducting the study.

The researchers began by genetically altering human mesenchymal stem cells (MSCs) in the lab to become vehicles for the cell-based anti-TNF delivery. They then injected the cells into mice that had been induced with RA and monitored them over a seven-day period, then compared the results to a group of animals treated with Etanercept®. The results showed that the anti-TNF therapy delivered by stem cells reversed or attenuated the arthritis inflammation on par with the Etanercept® — except that it did it faster.

“If this translates into fewer side-effects and/or lower compliance remains to be seen,” Dr. Mosca said. “In either case, these results illustrate the ability of stem cells to deliver proteins of therapeutic value and demonstrate their potential clinical utility in rheumatoid/osteoarthritis and other TNF-related diseases where anti-TNF biologic drugs have already shown promise.”

“The authors have shown the feasibility of a targeted approach to treatment using cells that are known to ‘home’ to damaged tissue,” said Anthony Atala, M.D., Editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. “The manuscript supports and demonstrates the potential of mesenchymal stem cells as a vehicle for cell-based gene delivery.”

###
The full article, “Comparison of Drug and Cell-Based Delivery—Engineered Adult Mesenchymal Stem Cells Expressing Soluble Tumor Necrosis Factor Receptor-II Prevent Arthritis in Mouse and Rat Animal Models,” can be accessed at http://www.stemcellstm.com.

About STEM CELLS Translational Medicine: STEM CELLS TRANSLATIONAL MEDICINE (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (http://www.StemCells.com), in its 31st year, is the world's first journal devoted to this fast paced field of research. The Oncologist® (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 18th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10635431.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Preliminary Research, Led By Dr. Vincent Giampapa, Finds Aged Adult Stem Cells Can Be Functionally Reprogrammed To Act Like Younger Cells
2. New Method for Mass-Producing RPE Cells Paves Way to Treating Age-Related Blindness
3. Sigma Life Science and the Culture Collections of Public Health England Collaborate to Distribute Cells and Cellular Extracts
4. New Way to Mass-produce Natural Cancer-killing Cells Offers Hope for Patients
5. Tenfold boost in ability to pinpoint proteins in cancer cells
6. Stem cells produce compact, regenerated bone in mandible transplants
7. Transplanted brain cells in monkeys light up personalized therapy
8. U of T engineering breakthrough promises significantly more efficient solar cells
9. Dr. Carlos Szajnert, Announced today his Commitment to Further Educate his Patients on the Benefits of Cord Blood Stem Cells
10. UCLA researchers further refine NanoVelcro device to grab single cancer cells from blood
11. Drogueria Americana, a Honduran Affiliate of GeneCell International, Presents to a Panel of More Than 100 Leading Dentist on Dental Pulp Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017 Dutch philosopher Koert van Mensvoort - ... the University of Technology in Eindhoven - has written a ,Letter to ... calls on humanity to avoid becoming a slave and victim to its own ... ... Dutch philosopher Koert van Mensvoort – founder of the Next Nature Network ...
(Date:4/19/2017)... ... 2017 , ... A number of new instruments have recently emerged to accommodate ... Protein and Cell Analysis Education Webinar Series , will focus on advances in ... and future applications. , Many flow cytometers have unique capabilities and the Attune ...
(Date:4/19/2017)... ... April 19, 2017 , ... ThermaGenix, the PCR Improvement ... adds to several other early achievements at ThermaGenix, including the business formation and ... , ThermaGenix will use proceeds from the Series A-1 round to:, ...
(Date:4/19/2017)... 19, 2017  As a Bronze Sponsor ... Summit ,  Proove® Biosciences, Inc. announces the ... and lifestyle factors to accurately predict prescription opioid ... Southern California (USC), the Interventional Pain Institute in ... results showing that Proove Opioid Risk® accurately identifies ...
Breaking Biology Technology:
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
Breaking Biology News(10 mins):